Table 1. Summary of steady-state voltage-dependence of HCN channels with and without cholesterol modulation.
| Isoform | Condition | V1/2 (mV) | V1/2 pre-pulse(mV) | k | k pre-pulse |
|---|---|---|---|---|---|
| HCN1 | Control | −102 ± 3 | −88 ± 3* | 10.1 ± 0.7 | 8.4 ± 0.9 |
| Depleted | −100 ± 3 | −89 ± 2*,‡ | 11.2 ± 1.4 | 6.9 ± 0.6 | |
| Mevastatin | −100 ± 6 | −90 ± 8*,‡ | 18.1 ± 4.9 | 9.3 ± 0.7 | |
| Enriched | −105 ± 3 | −84 ± 4*,‡ | 10.5 ± 0.5 | 13.4 ± 2.0 | |
| HCN2 | Control | −114 ± 3 | −118 ± 2 | 11.4 ± 2.3 | 6.5 ± 1.5 |
| Depleted | −115 ± 5 | −98 ± 3*,†,‡ | 10.4 ± 1.8 | 11.6 ± 2.6 | |
| Mevastatin | −118 ± 2 | −108 ± 4*,†,‡ | 17.8 ± 5.8 | 12.4 ± 1.6 | |
| Enriched | −117 ± 4 | −106 ± 2*,†,‡ | 14.5 ± 1.7 | 7.5 ± 1.0 | |
| HCN4 | Control | −121 ± 4 | −111 ± 2* | 14.5 ± 2.0 | 13.2 ± 1.5 |
| Depleted | −111 ± 3‡ | −107 ± 4‡ | 13.5 ± 0.7 | 12.3 ± 0.9 | |
| Mevastatin | N.D. | N.D. | N.D. | N.D. | |
| Enriched | −108 ± 2‡ | −103 ± 2*,†,‡ | 15.5 ± 2.2 | 14.2 ± 3.6 |
‡P < 0.05 vs. control no pre-pulse.
*P < 0.05 vs no-prepulse.
†P < 0.05 vs. control pre-pulse.